Suven Life Sciences Limited Share Price & Technical Analysis
SUVEN · ₹284.8 (+5.09%)
Healthcare / Drug Manufacturers - Specialty & Generic
₹284.8
+5.09%
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidat…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
28% return in May, 24% avg return in past 3 year May month.
58% return in 2026, 44% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -20% | 4% | -6% | 52% | 28% | – | – | – | – | – | – | – | 58% |
| 25 | 2% | -19% | 9% | 12% | 93% | 1% | 11% | -22% | -2% | -3% | -13% | -4% | 63% |
| 24 | 33% | -5% | -1% | 10% | -17% | 12% | 36% | -2% | -2% | -11% | 4% | -3% | 53% |
| 23 | -10% | -10% | -13% | 17% | -4% | 14% | 0% | 1% | 10% | 14% | 3% | -5% | 16% |
| 22 | -1% | -14% | 16% | -4% | -9% | -12% | 2% | -1% | -2% | -9% | 4% | 7% | -21% |
Monthly return % by calendar month · historical pattern, not a forecast
Bullish · Strong · Overbought
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
₹57.06B
P/E ratio
—
52W high
₹300.0
52W low
₹124.1
Volume
17,44,582
Beta
0.70
Related stocks in Healthcare
Ngl Fine-chem Ltd.
₹2,260
Frequently asked questions
- What is Suven Life Sciences Limited share price today?
- Suven Life Sciences Limited (SUVEN) last traded around ₹284.8 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SUVEN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SUVEN. Download the app for real-time alerts.
- How can I analyze Suven Life Sciences Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.